EPO and neoplasm: Therefore, we examined the growth of mammary carcinoma cells injected into the mammary fat pad and found an even more dramatic effect of erythropoietin blockade in our tumor xenograft studies, where R103A-EPO antagonist expression in cancer cells almost completely abrogated primary in vivo tumor formation.